+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nevro Corp (NVRO) - Product Pipeline Analysis, 2022 Update

  • PDF Icon

    Company Profile

  • 50 Pages
  • July 2022
  • GlobalData
  • Nevro Corp
  • ID: 5637059
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Nevro Corp (Nevro) is a medical device company, which is engaged in developing novel products that advance the quality of life for people suffering from chronic pain in trunks and limbs. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacological neuromodulation platform for the treatment of chronic pain. The Nevro Senza SCS system is commercially available in the US, Europe and Australia. The company offers products under Senza, Senza II, Senza Omnia and the Nevro logo brands. Nevro is developing HF10 therapy for treatment related to painful diabetic neuropathy and non-surgical refractory back pain. Nevro is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Nevro Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Nevro Corp Company Overview
  • Nevro Corp Company Snapshot
  • Nevro Corp Pipeline Products and Ongoing Clinical Trials Overview
  • Nevro Corp - Pipeline Analysis Overview
  • Business Description
  • Nevro Corp - Key Facts
  • Nevro Corp - Major Products a

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Saluda Medical Pty Ltd
  • Boston Scientific Corp
  • NeuSpera Medical Inc
  • Abbott Laboratories
  • Stimwave Technologies Inc
  • Medtronic Plc